Get the Daily Brief
Latest Biotech News
CRISPR therapy trims LDL and triglycerides in early human test…safety questions linger
An early clinical study of a CRISPR‑based gene editing therapy produced dramatic reductions in LDL cholesterol and triglycerides in a small cohort, signaling potential for one‑time editing to...
FDA expands fast‑track pilot: six more drugs added to national‑interest review
The FDA added six additional therapies to its Commissioner’s National Priority Voucher pilot, bringing the program’s total to 15 drugs slated for accelerated review. The agency said the pilot aims...
Recursion names new CEO as cash runway extends; Q3 losses widen
Recursion disclosed a leadership change and financial update as it reported mixed third‑quarter results. Co‑founder Chris Gibson will step down as CEO and become chairman; Najat Khan, PhD, the...
PD‑1 inhibitors after CD19 CAR‑T improve consolidation outcomes in NHL
A recent study led by Xue, Zhou and Chen evaluated sequential PD‑1 inhibitor therapy as consolidation following CD19 CAR‑T in relapsed or refractory non‑Hodgkin lymphoma and reported enhanced...
STAiR18 therapy boosts survival in multiple myeloma – new clinical data
Investigators led by Wu and colleagues reported that STAiR18 therapy improved survival outcomes in multiple myeloma patients in a recent study. The data show a measurable survival benefit tied to...
SGLT2 inhibitors prove beneficial across GFR and albuminuria strata in kidney disease
A landmark comprehensive analysis showed sodium‑glucose cotransporter‑2 (SGLT2) inhibitors confer kidney and cardiovascular benefits across a broad range of glomerular filtration rates and...
James Watson, co‑discoverer of DNA’s double helix, dies at 97
James D. Watson, who shared the 1962 Nobel Prize for the discovery of DNA’s double‑helix structure, died at age 97. Watson’s model, developed with Francis Crick and informed by Rosalind Franklin’s...
Pfizer wins Metsera: $10 billion takeover ends Novo Nordisk fight
Pfizer closed a $10 billion bid to acquire obesity drug developer Metsera, outbidding Novo Nordisk and ending a public, litigious bidding battle. The deal, announced late Friday, more than doubled...
Intellia pause... patient death prompts FDA clinical hold
Intellia disclosed the death of an elderly participant in its Phase III MAGNITUDE trial of nexiguran ziclumeran for transthyretin amyloidosis with cardiomyopathy, citing Grade 4 liver...
Merck’s oral PCSK9 pill rivals injectables: Phase 3 LDL drop to 60%
Merck reported Phase 3 results for Enlicitide, an oral, once-daily PCSK9 inhibitor, showing LDL cholesterol reductions up to 60% and that two-thirds of treated patients halved their LDL levels....
CRISPR gene edits cut lipids... early trials show dramatic reductions
Early human studies of CRISPR-based therapies targeting lipid pathways produced large reductions in LDL and triglycerides, and several Phase 1 programs targeting ANGPTL3 are now underway. A small...
PacBio’s long‑read sequencer cleared in China: Sequel II gets NMPA nod
PacBio and Berry Genomics secured Class III medical device registration from China’s NMPA for the Sequel II CNDx system—the first regulatory clearance for a clinical-grade long‑read sequencer. The...
Qiagen buys Parse Biosciences – single‑cell consolidation continues
Qiagen agreed to acquire Seattle-based Parse Biosciences for up to $280 million, folding a prominent single-cell sequencing vendor into a larger molecular tools company. Parse’s leadership and...
Swiss Rockets licenses CoolMPS: new western challenger in NGS instruments
Swiss Rockets secured an exclusive license to MGI/Complete Genomics’ CoolMPS sequencing chemistry for markets outside Asia‑Pacific and plans to launch CoolMPS-based sequencers as soon as next...
MIT LNP breakthrough: 100‑fold dose cut for influenza mRNA in mice
MIT researchers described a degradable cyclic amino ionizable lipid nanoparticle (LNP) that delivered an influenza mRNA vaccine in mice at roughly 1/100th the dose required by current FDA‑approved...
FDA expands fast‑track pilot: six more drugs gain national‑interest vouchers
The FDA added six additional therapies to its Commissioner’s National Priority Vouchers pilot, bringing the program total to 15 drugs selected for accelerated review under a national‑interest...
Thermo Fisher board OKs $5B buyback – capital returns after solid Q3
Thermo Fisher Scientific’s board authorized a $5 billion open‑market share repurchase with no expiration date, expanding a prior buyback and signaling confidence after reporting $11.12 billion in...
Intellia CRISPR trial death... dosing paused and FDA hits clinical hold
Intellia disclosed the death of an elderly participant in its Phase III MAGNITUDE program for nexiguran ziclumeran (nex‑z) and subsequently paused dosing and screening across two trials. The...
Pfizer wins Metsera: $10 billion takeover ends bidding war
Pfizer agreed to buy obesity‑drug developer Metsera for roughly $10 billion after upping its offer and outmaneuvering Novo Nordisk in a high‑profile bidding contest. The deal resolves a public...
Merck’s oral PCSK9 pill delivers injectable‑level LDL cuts – Phase 3 readout
Merck’s oral PCSK9 inhibitor, enlicitide, produced LDL cholesterol reductions up to 60% in a Phase 3 trial testing the pill on patients already taking statins, the company reported. The...